https://medicaldialogues.in/news/industry/pharma/fda-accepts-dupixent-dupilumab-for-priority-review-in-adults-with-prurigo-nodularissanofi-dupixent-under-usfda-priority-review-for-adults-with-prurigo-nodularis-93741